Real-world studies show RSV immunizations protect newborns in their first year of life - CIDRAP
Real-world studies show RSV immunizations protect newborns in their first year of life CIDRAP
Real-world studies show RSV immunizations protect newborns in their first year of life CIDRAP
How RSV Spreads in Older Adults: Signs, Risks, and Protection Tips The National Council on Aging (NCOA)
RSV Maternal Vaccine Halves Baby Intensive Care Admissions Medscape
RSV in Infants and Young Children Centers for Disease Control and Prevention | CDC (.gov)
Is RSV contagious? Everything you need to know about this virus. UCHealth
Respiratory syncytial virus (RSV) Infant Monoclonal Antibody Administration Extension KDHE, KS (.gov)
Respiratory Syncytial Virus Hospitalizations Among Adults in Thailand: A Nationwide Retrospective Observational Study (RSV-HAT) Wiley Online Library
Respiratory syncytial virus (RSV) in adults: risk and vaccination Hospital Clínic Barcelona
Mathematical analysis of a stochastic delay model for respiratory syncytial virus dynamics Nature
Newborn ICU admissions drop 50% in first year of RSV vaccine programme Open Access Government
Guillain-Barré Syndrome Following Respiratory Syncytial Virus (RSV) Infection in the Third Trimester: A Case Report of a Rare Entity Cureus
Catch Your Breath: Following your child’s heart—and breath Nation Thailand
Protect Yourself from RSV: Who Needs the Vaccine and Why It Matters The National Council on Aging (NCOA)
Respiratory Virus Vaccines: Clinical Guidance And Resources American Academy Of Family Physicians | AAFP
How RSV Spreads Centers for Disease Control and Prevention | CDC (.gov)
Nirsevimab linked to reduction in RSV-related antibiotic prescribing CIDRAP
The soluble G protein of respiratory syncytial virus promotes viral dissemination via TLR2-mediated NLRP3 priming and pyroptosis Nature
One immunization may protect newborns against 2 serious diseases CIDRAP
β2-adrenergic signaling controls neonatal respiratory syncytial virus infection by promoting viral clearance and airway protection Nature
CIDRAP Op-Ed: RSV—the middle child of respiratory season who deserves more attention CIDRAP
In vitro liquid-liquid phase separation induced by respiratory syncytial virus proteins and RNA Science | AAAS
Current and Emerging Strategies for the Prevention of Respiratory Syncytial Virus (RSV) Infections: A Comprehensive Review of Vaccines and Antibody Therapies Cureus
Analysis of DNA methyltransferase 3 alpha expression during respiratory syncytial virus strain A infection Nature
U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season Business Wire
The Evolving Landscape of Respiratory Syncytial Virus (RSV) Prophylaxis in Infants Cureus
RSV symptoms in older adults often linger, studies show CIDRAP
Short-term environmental changes and respiratory syncytial virus infection in Chile Nature
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV) Yahoo Finance
RSV facts you need to know: What to expect during its winter peak UT Physicians
RSV vaccine protects older adults, and drug protects babies, but less so over time, studies suggest CIDRAP
Nirsevimab monoclonal antibody for RSV well tolerated in infants, study suggests CIDRAP
When To Take a Baby With RSV to the Hospital Cleveland Clinic Health Essentials
Respiratory Syncytial Virus (RSV): A Comprehensive Overview From Basic Biology to Clinical Prevention and Control Wiley Online Library
Universal nirsevimab slashes RSV infant hospitalizations, study suggests CIDRAP
Getting the RSV vaccine during pregnancy is a game-changer for infant hospitalizations CIDRAP
Correlates of risk of respiratory syncytial virus disease: a prospective cohort study Nature
Respiratory syncytial virus (RSV) vaccination recommendations in older adults Ovid
Hospitalisation and healthcare burden of respiratory syncytial virus in adults over 50 years in France medRxiv
In 2023-24, RSV vaccines were 79% effective against virus-related blood clots in older adults, CDC estimates CIDRAP
Respiratory Virus Hospitalization Surveillance Network (RESP-NET) Centers for Disease Control and Prevention | CDC (.gov)